Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.. CLINICAL CANCER RESEARCH. 2023; 29(17)DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:10.400(Q1/1D).

Escuin D, López-Vilaró L, Bell O, Mora J, García-Valdecasas B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients.. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(17)DOI:10.3390/ijms241713293. PMID:37686099. IF:4.900(Q1/3D).

Fumagalli, C, Orellana, R, Bagué, S, Ferré, M, Gonzalez, A, Catasus, L, Llauger, J, Peiró, A, Alarcón, PZ, Majercakova, K, Terés, R, Karanian-Philippe, M, Tirode, F, Antonescu, CR. YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features. GENES CHROMOSOMES & CANCER. 2025; 64(7)DOI:10.1002/gcc.70059. PMID:40879254. IF:2.800(Q2/5D).

Paz-Ares, L, Veillon, R, Majem, M, Zhou, CC, Tang, KJ, Kim, SW, Richardson, G, Girard, N, Sanborn, RE, Mansfield, AS, Park, K, Schuchard, J, Diels, J, Sermon, J, Bhattacharya, A, Lorenzini, P, Wortman-Vayn, H, Knoblauch, RE, Agrawal, T, Baig, M, Ono, A, Sabari, JK. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. LUNG CANCER. 2026; 213DOI:10.1016/j.lungcan.2025.108788. PMID:41671629. IF:4.400(Q1/2D).

Mateos, L, Jiménez-Fonseca, P, Gallego, J, Lecumberri, A, Custodio, A, de Castro, EM, San Gil, RH, Montes, AF, Limon, ML, Vidal-Tocino, R, Cano, JM, Robles, JL, Gil, M, Eyzaguirre, DA, Zafra, GM, Mérida-García, AJ, Fernández, AF, Fernández, PR, Hierro, C, Riesco, MC, Araque, MG, Martín, MR, Pimentel, P, Visa, L, Cerdá, P, Granja, M, Blanco, ABR, Gutiérrez, L, Carmona-Bayonas, A. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. BRITISH JOURNAL OF CANCER. 2026; 134(3)DOI:10.1038/s41416-025-03264-2. PMID:41298815. IF:6.800(Q1/2D).

López-López, C, de Castro, EM, Montes, AF, Orozco, EJ, Peraita, SL, Vera, R, Cerdá, P, Calvo, M, Paredes, BG, de Mena, ML, La Casta, A, Gallego, J, Adeva, J, Cano, JMC, Ruiz-Casado, A, Vidal-Tocino, R, García-García, T, Pazo-Cid, R, Garrote, MR, Sastre, J. Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04010-z. PMID:40782167. IF:2.500(Q3/6D).

Molassiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, L, Stimamiglio, V, Alonzi, A, Tilola, SO, Bonizzoni, E, Vázquez, EB, Buchler, T, Cheng, Y, Christoph, DC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanová, M, Aapro, M. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. ANNALS OF ONCOLOGY. 2026; 37(2)DOI:10.1016/j.annonc.2025.10.017. PMID:41110696. IF:65.400(Q1/1D).

Gonzalez-Cao, M, Berciano-Guerrero, MA, Muñoz-Couselo, E, Manzano, JL, Cerezuela-Fuentes, P, Crespo, G, Soria, A, de Miguel, PA, Sanz, LG, de la Rosa, CA, Castaño, AG, Puértolas, T, Espinosa, E, Medina, J, Bellido, L, Berrocal, A, Majem, M, Castro, RL, Fernandez, LA, Garcia, F, de la Borbolla, MR, Algarra, SM, Márquez-Rodas, I. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04018-5. PMID:40841506. IF:2.500(Q3/6D).